Cost- effectiveness analysis of sacubitril/valsartan vs ena- lapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1:666 72. 147. Ollendorf DA, Sandhu AT, Pearson SD. Sacubitril- valsartan for the treatment of heart failure: effective- ness and value. JAMA Intern Med. 2016;176:249 50. 148. Kansal AR, Cowie MR, Kielhorn A, et al. Cost- effectiveness of ivabradine for heart failure in the United States. J Am Heart Assoc. 2016;5:e003221. 149. Clarkson EB, Linley A, Frank JS, et al. The implementation of a patient assistance program in a free clinic setting: a case report. J Health Care Poor Underserved. 2016;27:1183 91. 150. Armstrong PW, Pieske B, Anstrom KJ, et al. Ver- iciguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382:1883 93. 151. Zaman S, Zaman SS, Scholtes T, et al. The mor- tality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information lea ets. Eur J Heart Fail. 2017;19:1401 9. 152. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scienti c state- ment from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140: e294 324. 153. Seferovic PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position state- ment from the Heart Failure Association of the Euro- pean Society of Cardiology. Eur J Heart Fail. 2018;20: 853 72. 154. Zinman B, Wanner C, Lachin JM, et al. Empagli- ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117 28. 155. Neal B, Perkovic V, Mahaffey KW, et al. 